Although multiple studies have shown T reg cells are potential targets in cancer immunotherapy, there is still limited insight into the most selective approach for T reg cell depletion. CD25 had been ...
A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4. Background: CD4+ regulatory T cells (Tregs) ...
Development of a CCR8 monoclonal antibody to block CCR8 signaling and to abolish the immunosuppressive function of Treg for the treatment of cancers. Investigating the novel CD16A and epidermal growth ...
“Taken together, our studies suggest that 2B010 represents an anti-CD25 mAb with unique properties in that it deleted Treg from an inflammatory environment (GVHD) as well as from the TME” “Taken ...
Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is ...
The shared CD25 activation mechanism on regulatory and effector T cells has been a big challenge when designing immunotherapy drugs. Cancer Research UK scientists from University College London in ...
Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T cells (Tregs) in preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results